Feasibility of a Smart Device Application for Home-based Prehabilitation

Feasibility of a Smart Device Application for Home-based Prehabilitation in Patients Undergoing Lung Cancer Surgery: A Prospective Observational Pilot Study

NCT05363150•Seoul National University Hospital

View on ClinicalTrials.gov

Summary

To investigate the feasibility of a home-based exercise training program using a smartphone application in patients planning for cancer surgery, and to determine the effectiveness of this application on functional capacity.

Eligibility

Age

19 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult patients (19-70) who are scheduled for elective cancer surgery
•American Society of Anesthesiologists (ASA) physical status classification I or II
•Patients who can use a smartphone application
•Patients who can perform an exercise program for at least 3 weeks from the first visit to the preoperative clinic to elective surgery

Exclusion Criteria

•Patients who are unable to communicate
•Patients under the age of 19 and over 70
•Patients who have a major medical or psychiatric disorder that is expected to affect exercise
•Patients with contraindications to the general rehabilitation program

Key Dates

Start Date

June 1, 2022

Primary Completion Date

September 1, 2022

Completion Date

December 1, 2022

Last Updated

May 11, 2022

Enrollment

ESTIMATED participants

Conditions

CancerPrehabilitation

Contacts

Susie Yoon, PhD

CONTACT

+82-2-2072-1860 susiey87@gmail.com

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

NCT00026884

Malignant NeoplasmsHereditary Neoplastic Syndromes+3 more

View study

RECRUITINGPHASE2

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

NCT03375307

Advanced Bladder CarcinomaAdvanced Genitourinary System Carcinoma+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 11, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Feasibility of a Smart Device Application for Home-based Prehabilitation

Inclusion Criteria

Exclusion Criteria

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Magnetic Resonance Imaging of the Lung: Oncological Applications

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device